Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mol Cell Probes. 2021 Feb;55:101692. doi: 10.1016/j.mcp.2020.101692. Epub 2020 Dec 28.
The newly emerged coronavirus (SARS-CoV-2) continues to infect humans, and no effective treatment has yet been found. Antibody therapy is one way to control infection caused by COVID-19. However, the use of classical antibodies raises complex issues. Heavy chain antibodies (HCAbs) are single-domain antibodies derived from the Camelidae family. The variable part of these antibodies (Nanobodies or VHH) has interesting properties such as small size, cost-effective production, and good tissue permeability, causing VHH to be regarded as an antiviral therapeutics. However, the small size of nanobodies may lead to low antigen binding affinity and rapid renal clearance. In this systematic review, the application of nanobodies in the treatment of COVID-19 infection and other similar infections (MERS and SARS) was reviewed.
新出现的冠状病毒（SARS-CoV-2）继续感染人类，目前尚未找到有效的治疗方法。抗体疗法是控制 COVID-19 感染的一种方法。然而，使用经典抗体会引发复杂的问题。重链抗体（HCAbs）是源自骆驼科的单域抗体。这些抗体的可变部分（纳米抗体或 VHH）具有有趣的特性，如体积小、生产成本低和良好的组织通透性，这使得 VHH 被视为一种抗病毒治疗药物。然而，纳米抗体的体积小可能导致抗原结合亲和力低和快速肾清除。在本系统评价中，综述了纳米抗体在治疗 COVID-19 感染和其他类似感染（MERS 和 SARS）中的应用。
